Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the medical research outsourcing and chemical preparations sectors showed positive growth, while hospitals and blood products faced declines [2][13]. - The report notes that the innovative drug licensing transactions in China exceeded $60 billion in the first quarter of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. Important Industry News - The NMPA has launched a three-year "Spring Rain Action" to promote the transformation of clinical innovation achievements in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has received FDA approval, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has been approved by the FDA, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, becoming the first of its kind domestically [46]. Investment Suggestions - The report suggests focusing on innovative drug companies with core technology platforms and differentiated pipeline layouts, especially those expected to achieve positive catalysts at major academic conferences like AACR [5]. - It also recommends attention to the CXO/CDMO industry chain, which is expected to benefit from improved overseas R&D demand and order recovery [5].

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Insights - The company reported a revenue of 1.2 billion RMB in 2025, representing a 7% year-over-year increase, while the net profit attributable to the parent company was 180 million RMB, a decrease of 11% year-over-year [1][4]. - The revenue from flu vaccines was 1.12 billion RMB, reflecting a 4% year-over-year increase, despite a 27% decrease in production volume [2][4]. - The company is expected to see a steady recovery in vaccine sales in 2026, driven by government support and increased public awareness of vaccination [2][4]. Summary by Sections Financial Performance - In 2025, the gross margin was 77.8%, down 3.4 percentage points year-over-year, primarily due to decreased production volume affecting economies of scale [3]. - The net profit margin for 2025 was 15.2%, a decline of 3.0 percentage points year-over-year [3]. - The company adjusted its profit forecasts for 2026-2027, expecting net profits of 220 million RMB and 260 million RMB, respectively, which are reductions of 74% and 75% from previous estimates [4][11]. Market Outlook - The overall vaccine shipment rate improved to 83%, an increase of 16 percentage points year-over-year, indicating better market conditions towards the end of 2025 [2]. - The report anticipates significant growth potential in the Chinese flu vaccine market, supported by government initiatives and rising vaccination awareness among the public [2][4]. Valuation - The target price for the company is set at 23.68 RMB, reflecting a price-to-earnings ratio of 65 times for 2026, which is a premium compared to the median of comparable companies at 49 times [4][12].

Investment Rating - The report indicates a positive outlook for the biotech sector, particularly highlighting the first-time profitability of leading biotech companies, suggesting a shift towards sustainable profitability in the industry [2][3]. Core Insights - The biotech sector has shown resilience, with a weekly increase of 1.56%, outperforming the Shanghai and Shenzhen 300 index, which decreased by 1.41% [3][8]. - Leading biotech companies, such as BeiGene and Innovent Biologics, achieved their first annual profitability in 2025, marking a transition from valuation-driven to performance-driven growth in the domestic biotech market [3][12]. - The NewCo model is evolving, as evidenced by the acquisition agreement between Ouro Medicines and Gilead Sciences, which could generate significant revenue for the involved parties [3][13]. Market Weekly Review - The pharmaceutical and biotech sector saw a weekly increase of 1.56%, outperforming the Shanghai and Shenzhen 300 index, which fell by 1.41% [3][8]. - Sub-sectors such as medical research outsourcing (6.12%), raw materials (5.34%), and chemical preparations (2.88%) led the gains, while blood products (-2.95%), vaccines (-2.36%), and offline pharmacies (-1.63%) lagged [3][9]. - Notable stock performances included Meinohua (40.7%), Wanbangde (38.8%), and Fuxiang Pharmaceutical (27.6%) with significant gains, while Koyuan Pharmaceutical (-19.9%), *ST Changyao (-18.2%), and Duorui Pharmaceutical (-15.6%) faced declines [3][11]. Industry News and Key Company Announcements - Significant events include the announcement by Dize Pharmaceutical regarding promising clinical trial results for its drug in treating advanced non-small cell lung cancer [12]. - Innovent Biologics reported a revenue of 13.042 billion yuan for 2025, a 38.4% increase year-on-year, with product revenue growing by 44.6% [12][13]. - The report highlights various companies' financial performances, including a 316.29 billion yuan revenue for Heng Rui Pharmaceutical, reflecting a 13.02% year-on-year growth [13][14].

Investment Rating - The industry rating is maintained at "Overweight" [5][10] Core Insights - The vaccine industry is experiencing a transition from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term outlook remains positive driven by policy, demand, and technology [9][10][30] - Domestic companies like Zhifei Biological and Wantai Biological are making progress in multi-valent vaccines and genetically engineered recombinant vaccines, indicating differentiated technological paths and process upgrades [3] - GSK's hepatitis B vaccine is re-entering the Chinese market through a strategic partnership, highlighting multinational companies' flexible approaches to strengthen their vaccine business in China [3] Summary by Sections Domestic and International Vaccine Dynamics - Zhifei Biological's acellular pertussis-diphtheria-tetanus combined vaccine has entered Phase I clinical trials [3] - Wantai Biological's trivalent rotavirus subunit vaccine has received clinical trial approval [3] - GSK announced a strategic cooperation to reintroduce its hepatitis B vaccine in China [3] Market Performance - The vaccine sector saw a decline of 4.93% last week, with a cumulative drop of 18.64% since 2025 [4][12] - The overall pharmaceutical sector showed mixed performance, with the pharmaceutical index rising by 1.56% [4] Company Performance - Companies like Jindike, Olin Biological, and Wantai Biological performed well, while companies like CanSino and Liaoning Chengda lagged behind [5] Valuation - The vaccine sector's PE (ttm) was 65.37X, down 1.47X week-on-week, with a PB (lf) of 1.21X, also showing a slight decrease [8] Investment Recommendations - The vaccine industry is under pressure, with a focus on innovation and international expansion as key strategies for long-term growth [9][10][30] - Companies with strong R&D capabilities and differentiated product offerings are recommended for investment, particularly focusing on those with high technical barriers [10][30]

Core Viewpoint - The stock price of CanSino (688185.SH) has declined, closing at 67.71 yuan with a drop of 1.58%, currently in a state of underperformance [1] Group 1: Company Overview - CanSino was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 13, 2020, with an issuance of 24.8 million shares at a price of 209.71 yuan per share [1] - The total funds raised from the initial public offering (IPO) amounted to 5.201 billion yuan, with a net amount of 4.979 billion yuan after deducting issuance costs [1] - The final net fundraising amount exceeded the original plan by 3.979 billion yuan, with the initial plan set at 1 billion yuan for various projects including production base expansion and vaccine development [1] Group 2: Financial Details - The issuance costs for CanSino's IPO were 221 million yuan, with underwriting and sponsorship fees accounting for 205 million yuan [2] - CITIC Securities, a participating underwriter, received an allocation of 496,000 shares, representing 2.00% of the total shares issued, with an investment amount of 104 million yuan [2]

Core Viewpoint - The recent expansion of the National Immunization Program (NIP) in China, as outlined in the 15th Five-Year Plan, is expected to significantly benefit the vaccine industry, which is currently facing challenges such as declining vaccination rates and intense competition [3][5]. Group 1: National Immunization Program Expansion - The NIP aims to dynamically optimize the types of vaccines included, which is a cost-effective measure to combat infectious diseases and will be funded by the government [3][4]. - The inclusion of vaccines like the HPV vaccine in the NIP marks a significant step, but many internationally recommended vaccines for children and adults are still not covered in China [5][6]. - Current spending on childhood vaccines in China is only $50 per capita annually, compared to $585 in Argentina and $336 in Brazil, indicating a substantial gap in investment [5]. Group 2: Industry Challenges and Competition - The domestic vaccine industry is currently in a downturn, characterized by fierce price competition that has not led to increased vaccination rates [7][8]. - The issue of homogenized competition is identified as a root cause of the industry's "involution," where multiple companies produce the same vaccine, leading to market saturation [8]. - The global vaccine market is highly concentrated, with major companies like Merck, Pfizer, GSK, and Sanofi controlling 71% of the market share, suggesting a need for similar consolidation in China [8]. Group 3: Public Perception and Vaccination Willingness - Public willingness to vaccinate is declining, potentially due to trust issues regarding vaccine safety and effectiveness, necessitating deeper investigation into these concerns [9]. - Transitioning from self-paid to publicly funded vaccinations is expected to significantly increase vaccination rates by removing financial barriers and enhancing public trust [9]. Group 4: Improving Vaccination Accessibility - The vaccination system in China is shifting towards covering all life stages, but there are still barriers to increasing adult vaccination rates [10][11]. - The ideal model for increasing vaccination rates involves integrating vaccination services into family doctor systems, which have proven effective in other countries [11]. - Current regulations on vaccination service points may hinder the expansion of vaccination services, suggesting a need for more flexible requirements to encourage participation from healthcare providers [12].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it highlights significant developments that may influence future ratings [2]. Core Insights - The invasive brain-machine interface (BMI) has received regulatory approval, marking a milestone in the domestic industry and indicating a shift from conceptual research to clinical application. This technology is expected to enhance the quality of life for patients with cervical spinal cord injuries [2][10]. - The report emphasizes the importance of focusing on specialized medical service providers with core neurosurgical clinical resources and data access, as well as innovative medical device companies with invasive BMI technology platforms [2]. Market Weekly Review - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% from March 9 to March 13, underperforming the CSI 300 index, which rose by 0.19%. Notable performers included medical consumables (up 4.1%), active pharmaceutical ingredients (up 1.32%), and vaccines (up 1.29%), while medical devices (down 2.04%), medical research outsourcing (down 1.63%), and chemical preparations (down 0.82%) lagged behind [7][8]. - Individual stock performances showed significant gains for Jiuan Medical (up 20.1%), Baolait (up 17.8%), and Haitai Biological (up 17%), while Huakang Medical (down 6.9%), ST Weiming (down 6.8%), and Yirui Technology (down 6.7%) faced notable declines [10]. Industry News and Key Company Announcements Important Industry Events - On March 13, the National Medical Products Administration approved the innovative product registration application for the implanted brain-machine interface hand function compensation system by Boruikang Medical, marking the global first for invasive BMI medical devices entering clinical application [10][11]. Industry News - Eli Lilly announced plans to invest $3 billion over the next decade to expand its supply chain capacity in China, focusing on local production and supply systems for oral solid formulations, including the GLP-1 receptor agonist orforglipron [11]. - GlaxoSmithKline (GSK) and Alfasigma entered a licensing agreement for the development and commercialization of linerixibat, a trial drug for primary biliary cholangitis, with GSK receiving an upfront payment of $300 million [12]. Company Announcements - Junshi Biosciences reported a total revenue of 2.498 billion yuan for 2025, a year-on-year increase of 28.23%, but also a net loss of 875 million yuan [11]. - Xizang Pharmaceutical announced a total revenue of 2.982 billion yuan for 2025, a year-on-year increase of 6.23%, with a proposed cash dividend of 563 million yuan [11]. - Aide Pharmaceutical projected a total revenue of 1.197 billion yuan for 2025, reflecting an 8% year-on-year growth, driven by operational efficiency improvements and product approvals [11].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it highlights significant developments that may influence future ratings [2]. Core Insights - The invasive brain-computer interface (BCI) has received regulatory approval, marking a milestone in the domestic BCI industry, transitioning from concept development to clinical application. This product is designed for patients with quadriplegia due to cervical spinal cord injuries and utilizes minimally invasive implantation and wireless communication technology [2][10]. - The report suggests focusing on specialized medical service providers with core neurosurgical clinical resources and data access, as well as innovative medical device companies with invasive BCI technology platforms [2]. Market Weekly Review - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% from March 9 to March 13, underperforming the CSI 300 index, which rose by 0.19%. Notable performers included medical consumables (up 4.1%), raw materials (up 1.32%), and vaccines (up 1.29%), while medical devices (down 2.04%), medical research outsourcing (down 1.63%), and chemical preparations (down 0.82%) lagged behind [7][8]. - Individual stock performances showed significant gains for Jiuan Medical (up 20.1%), Baolait (up 17.8%), and Haitai Biological (up 17%), while Huakang Medical (down 6.9%), ST Weiming (down 6.8%), and Yirui Technology (down 6.7%) faced notable declines [10]. Industry News and Key Company Announcements Important Industry Events - On March 13, the National Medical Products Administration approved the innovative product registration application for the implanted brain-computer interface hand function compensation system by Boruikang Medical, marking the global first for invasive BCI medical devices entering clinical application [10]. Industry News - Eli Lilly announced plans to invest $3 billion over the next decade to expand its supply chain capacity in China, focusing on local production and supply systems for oral solid formulations, including the GLP-1 receptor agonist orforglipron [11]. - GlaxoSmithKline (GSK) and Alfasigma entered a licensing agreement for the development and commercialization of linerixibat, a trial drug for primary biliary cholangitis, with GSK receiving an upfront payment of $300 million [12]. Company Announcements - Junshi Biosciences reported a total revenue of 2.498 billion yuan for 2025, a year-on-year increase of 28.23%, but a net loss of 875 million yuan [11]. - Tibet Pharmaceutical achieved a total revenue of 2.982 billion yuan for 2025, a year-on-year increase of 6.23%, with a proposed cash dividend of 563 million yuan [11]. - Aide Pharmaceutical projected a total revenue of 1.197 billion yuan for 2025, reflecting an 8% year-on-year growth, driven by operational efficiency improvements and product approvals [11].

Investment Rating - The industry rating is maintained at "Overweight" [2][10] Core Insights - The vaccine industry is transitioning from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term outlook remains positive driven by policy, demand, and technology [10][30] - The "14th Five-Year Plan" emphasizes high-quality development and full lifecycle immunization opportunities for the vaccine industry, indicating a shift towards a comprehensive immunization service system covering all age groups [4][10] - The industry is experiencing performance differentiation among companies, with a focus on innovative vaccines and multi-valent products to enhance competitiveness [9][10] Market Performance - The vaccine sector saw a 1.29% increase last week, while the overall pharmaceutical sector declined by 0.22% [5][12] - Year-to-date, the vaccine sector has experienced a cumulative decline of 13.18% [5][12] Valuation Metrics - The vaccine sector's PE (ttm) is 65.37X, down 1.47X week-on-week, with a one-year range of 31.95X to 111.89X [8][23] - The PB (lf) stands at 1.21X, a decrease of 0.03X from the previous week, with a one-year range of 1.66X to 2.15X [8][23] Investment Recommendations - The vaccine industry is under pressure, with performance still in a bottoming phase; however, companies are adjusting their pipeline strategies to focus on technological innovation and new vaccine development [9][27] - Long-term focus should be on companies with strong R&D capabilities and differentiated product offerings, with a recommendation to pay attention to companies like CanSino [10][30]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事會認為，香港沃森是海外業務拓展的先行者，擁有豐富的國際化運營經驗。 透過本次合作，本公司將藉助香港沃森生物多年深耕積累的海外市場資源及成熟 完善的分銷網絡，加快推動產品進軍東南亞、拉丁美洲、中東及南半球其他地區 市場。 1 （股份代號：2627） 自願性公告 訂立戰略合作協議 本公告由江蘇中慧元通生物科技股份有限公司（「本公司」或「中慧生物」，連同其 附屬公司，統稱「本集團」）自願刊發，以告知本公司股東及潛在投資者有關本集 團最新業務發展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司與沃森生物香港有限公司 （「香港沃森」）訂立有關亞單位流感疫苗海外市場拓展的戰略合作協議（「戰略合作 協議」）。 戰略合作協議 根據戰略合作協議，雙方將就本集團研發產品的海外市場註冊、銷售及商業化開 展深度合作。本次海外拓展的核心產品為本集團自主研發的三價亞單位流感疫苗 （惠爾康欣3）（「該產品」）。該 ...